News | Molecular Imaging | March 02, 2017

Gamma Medica Expands Into European Breast Imaging Market

Partnership with medical supplies distributor enables women in the United Kingdom, Ireland and Channel Islands access to LumaGEM Molecular Breast Imaging for secondary breast cancer screening

Gamma Medica, European breast imaging market, LumaGem MBI, molecular breast imaging, Hospital Services Limited

March 2, 2017 — Gamma Medica announced it has partnered with Hospital Services Limited (HSL), a Dublin, Ireland-based established medical device company that distributes, installs and services radiology capital equipment and medical devices. This partnership will provide women with dense breast tissue access to Gamma Medica’s LumaGEM Molecular Breast Imaging (MBI) system in the United Kingdom, Ireland and the Channel Islands.

Women are eligible for the United Kingdom’s National Health Service (NHS) breast screening program at age 50-79 years, with women being invited to be screened every three years. Similarly in Ireland, women 50-69 years old are eligible for breast screenings every two years. Dense breast tissue not only increases the risk of developing breast cancer, but decreases the visibility of a cancer on conventional mammograms and other forms of anatomical imaging devices. Dense breast tissue and cancer both appear white on mammograms, making it difficult to distinguish between the two. This may lead to false negatives, unwarranted biopsies or delayed diagnoses.

Ideal for dense breast tissue, MBI significantly improves early detection of breast cancer in women with dense breast tissue. The technology has proven to be as effective as a secondary screening method compared to ultrasound or magnetic resonance imaging (MRI), with far fewer false positives. Peer-reviewed clinical research reports the use of LumaGEM MBI reduces the need for tissue biopsies by 50 percent compared to other modalities. MBI is also more comfortable and better tolerated by most patients than conventional mammography or MRI.

A retrospective study, which complemented earlier published prospective clinical research, was published in the American Journal of Roentgenologys August 2016 issue. This retrospective study monitored over 1,700 women with dense breast tissue over a three-year period. The study confirmed LumaGEM’s additional cancer detection rate of 7.7 cancers per 1,000, an increase from three cancers per 1,000 with mammography alone. The study also concluded that of the additional breast cancers found, approximately 85 percent were invasive and node negative, indicating they were detected at an early stage and therefore presented the patient with the likelihood of a better prognosis.

For more information: www.gammamedica.com

Related Content

iCAD, PowerLook Tomo Detection, computer-aided detection software, CAD, digital breast tomosynthesis, DBT, RSNA 2017
Technology | Computer-Aided Detection Software | March 27, 2017
March 27, 2017 — iCAD announced that PowerLook Tomo Detection received Premarket Approval (PMA) from the U.S.
GE Healthcare, Senographe Pristina mammography system, launch, RSNA 2017, patient comfort
News | Mammography | March 24, 2017
GE Healthcare announced the launch of its new Senographe Pristina mammography system, designed to make breast screening...
Solis Mammography, minimize recall rates, false positives, breast cancer, women's health
News | Mammography | March 16, 2017
Solis Mammography recently released a statement taking issue with incorrectly interpreted terminology used by reporters...
Parascript, AccuDetect CAD for Mammography, computer-aided detection, NCoBC 2017
News | Computer-Aided Detection Software | March 15, 2017
Parascript will exhibit at the National Consortium of Breast Centers (NCoBC) 27th Conference, March 11-17, 2017, in Las...
iCAD, Xoft Axxent Electronic Brachytherapy System, eBx, 3,000 early-stage breast cancer patients, Miami Breast Cancer Conference
News | Brachytherapy Systems | March 15, 2017
CAD Inc. announced that more than 3,000 early-stage breast cancer patients have been treated with intraoperative...
reducing radiation therapy, breast cancer, cut treatment costs, Duke Cancer Institute study
News | Radiation Therapy | March 14, 2017
March 14, 2017 — Over half of older women with early stage breast cancer received more...
Hologic, ECR 2017, breast cancer screening solutions, Affirm prone biopsy system

The Affirm prone biopsy system. Image courtesy of Hologic.

News | Breast Imaging | March 14, 2017
Hologic Inc. highlighted its portfolio of innovative breast cancer screening and interventional products, including new...
Solis Mammography, Texas, HB 1036, insurance coverage, 3-D mammography, tomosynthesis
News | Mammography | March 09, 2017
Solis Mammography, an independent provider of breast imaging services, believes that an educated patient makes the best...
tomosynthesis, breast imaging

Image courtesy of Hologic

Feature | Breast Imaging | March 02, 2017
New research presented by Stephen Rose, M.D., chief medical officer of Solis Mammography and president of Rose Imaging...
Overlay Init